^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC)

Published date:
06/28/2021
Excerpt:
In addition, the ccRCC cells were exposed to DDP treatment, and we surprisingly found that upregulation of CXCR4 increased DDP-resistance in ccRCC cells.
DOI:
10.1080/21655979.2021.1943112